Alectinib halts lung cancer growth more than a year longer than crizotinib

Via Top Health News -- ScienceDaily

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects.

View original post here:

%d bloggers like this: